---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-007746"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T00:22:02.318663+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics Q1 cash $65M; uproleselan Phase 3 trial on track for H1 2024 survival trigger

## Summary
- Cash and equivalents $65.0M as of March 31, 2023, up from $47.9M at Dec 31, 2022; raised $28.7M via ATM.
- R&D expenses fell to $5.4M from $9.6M YoY on lower clinical trial costs after Phase 3 enrollment completed.
- Phase 3 uproleselan study continues; final overall survival event trigger projected within first half of 2024.
- Cash runway expected to fund operations into late Q4 2024.

## SEC filing metadata
- accession: 0001558370-23-007746
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000155837023007746/0001558370-23-007746-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000155837023007746/glyc-20230503x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-007746
- JSON: https://secwatch.observer/filing/0001558370-23-007746.json
- Plain text: https://secwatch.observer/filing/0001558370-23-007746.txt

## Key facts
- Earnings Releases
  CRESCENT BIOPHARMA, INC. reported financial results for the first quarter ended March 31, 2023.
  - Period: the first quarter ended March 31, 2023
  - Result: reported results
  source text: On May 3, 2023, GlycoMimetics, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837023007746/0001558370-23-007746-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.